Barr receives ANDA approval for two erythromycin compounds
Executive Summary
Barr's ANDAs for erythromycin delayed-release 333 mg capsule shaped and round shaped tablets were approved May 16, and its ANDA for erythromycin stearate 500 mg taba was approved May 15. Bar already markets erythromycin stearate 250 mg tabs. Barr will be the first generic firm to to sell erythromycin delayed-release 333 mg tab as a multisource product. Boots' E-Mycin and Abbott's Ery-Tab are marketed as branded versions of erythromycin delayed-release 333 mg and 250 mg tabs. Barr has alleged that FDA has intentionally delayed approval of its erythromycin delayed-release ANDAs as well as other applications in order to retaliate against the firm for testifying about problems with FDA's Division of Generic Drugs. FDA has told Barr that it must conduct a second bioequivalence study for its pending ANDA for a 250 mg tab. Barr received ANDA approval for the 500 mg tab in November 1988.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.